Last reviewed · How we verify
Tinzaparin or unfractionated heparin — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Tinzaparin or unfractionated heparin (Tinzaparin or unfractionated heparin) — Assistance Publique - Hôpitaux de Paris.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tinzaparin or unfractionated heparin TARGET | Tinzaparin or unfractionated heparin | Assistance Publique - Hôpitaux de Paris | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tinzaparin or unfractionated heparin CI watch — RSS
- Tinzaparin or unfractionated heparin CI watch — Atom
- Tinzaparin or unfractionated heparin CI watch — JSON
- Tinzaparin or unfractionated heparin alone — RSS
Cite this brief
Drug Landscape (2026). Tinzaparin or unfractionated heparin — Competitive Intelligence Brief. https://druglandscape.com/ci/tinzaparin-or-unfractionated-heparin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab